K. Park

A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.

A. Iasonos, P. Sabbatini, C. Aghajanian, 2008, European journal of gynaecological oncology.

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer

M. Rubin, H. Klocker, J. Mosquera, 2013, Prostate Cancer and Prostatic Disease.

Molecular alterations in prostate cancer and association with MRI features

M. Rubin, A. Sboner, J. Mosquera, 2015, Prostate Cancer and Prostatic Diseases.

Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets.

M. Gerstein, M. Rubin, A. Sboner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients

H. Kuerer, I. Bedrosian, A. Caudle, 2018, Annals of Surgical Oncology.

Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets.

M. Gerstein, M. Rubin, A. Sboner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.